Ivonescimab Injection + Pembrolizumab Injection
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Oct 26, 2023 → Dec 31, 2029
NCT ID
NCT05899608About Ivonescimab Injection + Pembrolizumab Injection
Ivonescimab Injection + Pembrolizumab Injection is a phase 3 stage product being developed by Summit Therapeutics for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05899608. Target conditions include Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06767514 | Phase 3 | Recruiting |
| NCT05899608 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer